Research Reports in Development. The Virus Project has begun research on summarizing the 73 antiviral therapies in phase 2 or greater. This list includes:
- 4D Pharma
- AbbVie
- Acer Therapeutics
- Alexion Pharmaceuticals
- Ansun Biopharma
- Applied Therapeutics
- ARMS Pharmaceutical
- AstraZeneca
- Atea Pharmaceuticals
- Athersys
- aTyr Pharma
- Bausch Health
- BerGenBio; ACCORD study
- Beth Israel Deaconess
- Biohaven Pharmaceuticals, Inc.
- Blade Therapeutics
- CalciMedica
- Capricor Inc.
- Celltex
- Celularity
- Chimerix
- CTI Biopharma
- CytoDyn
- Eiger Biopharmaceuticals
- Eli Lilly
- Eli Lily/ Incyte
- Ensysce Biosciences
- Evelo Biosciences
- Exvastat Ltd/ Global sponsors
- Ferring Pharmaceuticals Inc.
- FUJIFILM Toyama Chemical Co
- Gilead
- GSK
- Hope Biosciences
- Humanigen
- I-Mab Biopharma
- Immunic, Inc.
- Implicit Bioscience
- InflaRx N.V.
- Insmed Inc.
- Johnson & Johnson
- Lattice Biologics
- Laurent Pharmaceuticals
- Mallinckrodt Pharmaceuticals
- Mateon Therapeutics
- Merck & Co., Inc
- Mesoblast
- NeuroRx
- Novartis / Incyte
- Novartis; other research sponsors
- OctaPharma
- OncoImmune
- Ono Pharmaceutical Co., Ltd.
- Partner Therapeutics (PTx)
- Pfizer Inc.
- Pharming
- Pulmotect, Inc.
- RedHill Biopharma
- Regeneron
- Ridgeback Biotherapeutics
- Roche
- Roivant Sciences
- Romark Laboratories
- Sanofi
- Swedish Orphan Biovitrum
- Synairgen
- Takeda Pharmaceutical
- Vanda Pharmaceuticals
- Washington University School of Medicine
- Yamanouchi Pharmaceutical Co.
- ZymoGenetics, Inc